Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CAROL R REDILLAS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1629023908
CMS profile
551612
Location
CHALMETTE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$29,356.17

192 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 192 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CAROL R REDILLAS

NPI 1629023908 · CMS profile ID 551612

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CHALMETTE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 192 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1629023908?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CAROL R REDILLAS, NPI 1629023908, CMS profile ID 551612. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 192 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629023908?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). CAROL R REDILLAS, NPI 1629023908, CMS profile ID 551612. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 192 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629023908?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
CAROL R REDILLAS, NPI 1629023908, CMS profile ID 551612, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 192 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1629023908?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

192 matching records · $29,356.17 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 192 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 192.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $9.9506/16/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891433539 CMS
Amgen Inc. $24.4106/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939470515 CMS
Lilly USA, LLC $15.1706/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917934385 CMS
ABBVIE INC. $10.0306/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891433533 CMS
SK Life Science, Inc. $4.1106/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940715675 CMS
SK Life Science, Inc. $20.3306/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940715679 CMS
Teva Pharmaceuticals USA, Inc. $23.8306/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954525337 CMS
ABBVIE INC. $17.6606/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891433531 CMS
Collegium Pharmaceutical, Inc. $15.9106/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914580927 CMS
Lundbeck LLC $23.2206/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945793541 CMS
ABBVIE INC. $20.8705/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891433529 CMS
Amgen Inc. $25.6305/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939470513 CMS
Biohaven Pharmaceutical Holding Company Ltd. $5.1005/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923710229 CMS
Biohaven Pharmaceutical Holding Company Ltd. $13.4005/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923710227 CMS
Neurelis, Inc. $20.3105/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950157475 CMS
Biohaven Pharmaceutical Holding Company Ltd. $16.7105/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923710223 CMS
Biohaven Pharmaceutical Holding Company Ltd. $2.7805/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923710225 CMS
Lilly USA, LLC $900.0005/19/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917932475 CMS
ABBVIE INC. $16.1905/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891433527 CMS
SK Life Science, Inc. $22.3505/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940715659 CMS
SK Life Science, Inc. $2.2705/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940715663 CMS
Teva Pharmaceuticals USA, Inc. $31.2005/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954525177 CMS
ABBVIE INC. $26.2405/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891433525 CMS
ABBVIE INC. $2,400.0005/04/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891433519 CMS
ABBVIE INC. $11.1205/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891433521 CMS
ABBVIE INC. $23.5005/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891433523 CMS
ABBVIE INC. $17.9505/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891433517 CMS
Amgen Inc. $18.0505/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939470511 CMS
Biohaven Pharmaceutical Holding Company Ltd. $11.4404/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923710221 CMS
ABBVIE INC. $19.7704/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891433515 CMS
ABBVIE INC. $10.0104/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891433513 CMS
Collegium Pharmaceutical, Inc. $12.4104/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914580925 CMS
ABBVIE INC. $17.8504/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891433511 CMS
Biohaven Pharmaceutical Holding Company Ltd. $49.7204/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923710219 CMS
Biohaven Pharmaceutical Holding Company Ltd. $5.3304/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923710217 CMS
SK Life Science, Inc. $17.5304/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940715639 CMS
Teva Pharmaceuticals USA, Inc. $18.7604/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954525173 CMS
ABBVIE INC. $19.1804/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891433509 CMS
Lilly USA, LLC $2,025.0004/12/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917933259 CMS
Lilly USA, LLC $20.5904/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917930747 CMS
Amgen Inc. $17.9104/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939470527 CMS
Lundbeck LLC $11.5404/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945793537 CMS
ABBVIE INC. $13.0304/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891433507 CMS
Biohaven Pharmaceutical Holding Company Ltd. $21.5104/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923710215 CMS
ABBVIE INC. $18.7203/31/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891433503 CMS
ABBVIE INC. $2,400.0003/31/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891433505 CMS
ABBVIE INC. $23.9703/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891433501 CMS
UPSHER-SMITH LABORATORIES LLC $13.6403/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 912298805 CMS
ABBVIE INC. $18.5603/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891433499 CMS
Amgen Inc. $21.4403/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939470525 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $51,613.71 197
PY2020 $48,662.54 199
PY2021 $53,186.83 222
PY2022 $29,356.17 192
PY2023 $3,067.85 107
PY2024 $2,886.27 75
PY2025 $3,399.96 76

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $419.21 2
PY2025 Principal investigator $174,145.57 55
PY2024 Principal investigator $86,193.40 7
PY2023 Recipient $261,059.40 4
PY2023 Principal investigator $77,836.50 3
PY2022 Principal investigator $238,382.80 18
PY2021 Principal investigator $382,478.33 26
PY2020 Principal investigator $155,481.30 4
PY2019 Principal investigator $1,764.71 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

57 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Innovation $1,140.00 12/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293373
Principal investigator 1 Ipsen Innovation $990.00 12/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293389
Principal investigator 1 Ipsen Innovation $3,695.00 12/30/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293393
Principal investigator 1 Ipsen Innovation $3,345.00 12/03/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293375
Principal investigator 1 Ipsen Innovation $3,226.00 12/03/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293377
Principal investigator 1 Ipsen Innovation $3,345.00 12/03/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293379
Principal investigator 1 Ipsen Innovation $990.00 12/03/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293381
Principal investigator 1 Ipsen Innovation $990.00 12/03/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293383
Principal investigator 1 Ipsen Innovation $990.00 12/03/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293385
Principal investigator 1 Ipsen Innovation $4,822.00 12/03/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293387
Principal investigator 1 Ipsen Innovation $4,164.00 12/03/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293391
Principal investigator 1 Ipsen Innovation $990.00 10/22/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293301
Principal investigator 1 Ipsen Innovation $4,164.00 10/22/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293303
Principal investigator 1 Ipsen Innovation $3,226.00 10/22/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293305
Principal investigator 1 Ipsen Innovation $990.00 10/22/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293307
Principal investigator 1 Ipsen Innovation $3,695.00 10/22/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293309
Principal investigator 1 Ipsen Innovation $4,164.00 10/22/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293311
Principal investigator 1 Ipsen Innovation $3,695.00 10/22/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293313
Principal investigator 1 Ipsen Innovation $4,822.00 10/22/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293315
Principal investigator 1 Ipsen Innovation $4,822.00 10/22/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293317
Principal investigator 1 Ipsen Innovation $2,568.00 10/22/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293319
Principal investigator 1 Ipsen Innovation $4,164.00 10/22/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293321
Principal investigator 1 Ipsen Innovation $3,226.00 10/22/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293323
Principal investigator 1 Ipsen Innovation $4,164.00 10/22/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293325
Principal investigator 1 Ipsen Innovation $990.00 10/22/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293327
Principal investigator 1 Ipsen Innovation $990.00 10/22/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293329
Principal investigator 1 Ipsen Innovation $2,568.00 10/22/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293331
Principal investigator 1 SK Life Science, Inc. $3,000.00 09/24/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
YKP3089C049 No dispute reported 06/30/2026 1252275733
Principal investigator 1 SK Life Science, Inc. $1,500.00 09/24/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
YKP3089C049 No dispute reported 06/30/2026 1252275735
Principal investigator 1 SK Life Science, Inc. $500.00 09/24/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
YKP3089C049 No dispute reported 06/30/2026 1252275737
Principal investigator 1 SK Life Science, Inc. $1,500.00 09/24/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
YKP3089C049 No dispute reported 06/30/2026 1252275785
Principal investigator 1 SK Life Science, Inc. $3,000.00 09/24/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
YKP3089C049 No dispute reported 06/30/2026 1252275787
Principal investigator 1 Merz Pharmaceuticals, LLC $15,000.00 09/17/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647362
Principal investigator 1 Merz Pharmaceuticals, LLC $2,500.00 09/17/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine No dispute reported 06/30/2026 1232647366
Principal investigator 1 Ipsen Innovation $15,000.00 09/15/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293229
Principal investigator 1 Ipsen Innovation $3,000.00 09/15/2025 Non-covered Recipient Entity
Ki Health Partners, Llc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184293231
Principal investigator 1 Merz Pharmaceuticals, LLC $15,000.00 09/10/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647368
Principal investigator 1 Merz Pharmaceuticals, LLC $2,500.00 09/10/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine No dispute reported 06/30/2026 1232647372
Principal investigator 1 H. Lundbeck A S $3,354.00 07/09/2025 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251765398
Principal investigator 1 H. Lundbeck A S $2,534.00 07/09/2025 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251765402
Principal investigator 1 H. Lundbeck A S $11,500.00 07/09/2025 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251765406
Principal investigator 1 H. Lundbeck A S $3,000.00 07/09/2025 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251765410
Recipient Ipsen Innovation $293.21 06/25/2025 Covered Recipient Physician A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291308
Recipient Ipsen Innovation $126.00 06/25/2025 Covered Recipient Physician A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291310
Principal investigator 1 SK Life Science, Inc. $12,500.00 04/23/2025 Non-covered Recipient Entity
KI HEALTH PARTNERS LLC
YKP3089C049 No dispute reported 06/30/2026 1252275703
Principal investigator 1 H. Lundbeck A S $52.00 03/07/2025 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251765393
Principal investigator 1 H. Lundbeck A S $3.99 03/06/2025 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251765385
Principal investigator 1 H. Lundbeck A S $5.97 03/06/2025 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251765389
Principal investigator 1 H. Lundbeck A S $370.36 03/05/2025 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251765355
Principal investigator 1 H. Lundbeck A S $238.89 03/05/2025 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251765359
Principal investigator 1 H. Lundbeck A S $123.64 03/05/2025 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251765364
Principal investigator 1 H. Lundbeck A S $26.05 03/05/2025 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251765368
Principal investigator 1 H. Lundbeck A S $25.00 03/05/2025 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251765372
Principal investigator 1 H. Lundbeck A S $126.60 03/05/2025 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251765376
Principal investigator 1 H. Lundbeck A S $17.50 03/05/2025 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251765379
Principal investigator 1 H. Lundbeck A S $23.61 03/05/2025 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251765382
Principal investigator 1 H. Lundbeck A S $808.96 02/07/2025 Covered Recipient Teaching Hospital
CLEVELAND CLINIC HOSPITAL
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251765351